palmidrol has been researched along with Allodynia in 34 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA." | 7.85 | A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017) |
| " The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin." | 7.71 | Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. ( Colleoni, M; Conti, S; Costa, B; Giagnoni, G; Parolaro, D, 2002) |
| " (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)." | 7.70 | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998) |
| ", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA." | 3.85 | A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017) |
| " Intraplantar injection of CAR led to a time-dependent development of peripheral inflammation, in terms of paw edema, cytokine release in paw exudates, nitrotyrosine formation, inducible nitric oxide synthase and cyclooxygenase-2 expression." | 3.83 | A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Gugliandolo, E; Impellizzeri, D; Siracusa, R, 2016) |
| "The analgesic and anti-hyperalgesic effects of cannabinoid- and vanilloid-like compounds, plus the fatty acid amide hydrolase (FAAH) inhibitor Cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597), and acetaminophen, were evaluated in the phenyl-p-quinone (PPQ) pain model, using different routes of administration in combination with opioid and cannabinoid receptor antagonists." | 3.73 | Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. ( Cichewicz, DL; Haller, VL; Welch, SP, 2006) |
| " The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin." | 3.71 | Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. ( Colleoni, M; Conti, S; Costa, B; Giagnoni, G; Parolaro, D, 2002) |
| " (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)." | 3.70 | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998) |
| "Obesity is associated with augmented peripheral inflammation and pain sensitivity in response to inflammatory stimulation, but the underlying mechanisms remain unclear." | 1.40 | Down-regulation of PPARα in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats. ( Fu, Z; Li, D; Liang, L; Wang, J; Zhang, Q; Zhao, L, 2014) |
| " The lipidic nature and large particle size of PEA in the native state may limit its solubility and bioavailability when given orally, however." | 1.40 | Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Impellizzeri, D; Siracusa, R, 2014) |
| "Spinal AEA reduces neuropathic pain by acting at both cannabinoid CB1 receptors and transient receptor potential vanilloid-1 (TRPV1) channels." | 1.39 | Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. ( Cristino, L; De Petrocellis, L; Di Marzo, V; Korostynski, M; Makuch, W; Malek, N; Petrosino, S; Przewlocka, B; Slezak, M; Starowicz, K; Zychowska, M, 2013) |
| "To induce hyperalgesia, rat paws were treated with intraplantar prostaglandin E2 (PGE2, 2μg)." | 1.39 | Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors. ( Duarte, ID; Pacheco, Dda F; Romero, TR, 2013) |
| " In addition, the dosage of nitrite in the homogenized paw, as determined by colorimetric assay, indicated that exogenous PEA is able to induce NO release." | 1.38 | Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats. ( Cortes, SF; Duarte, ID; Galdino, GS; Perez, AC; Resende, LC; Romero, TR; Silva, GC, 2012) |
| "Inflammatory hyperalgesia was measured following intraplantar injection of carrageenan." | 1.35 | Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. ( Alexander, SP; Barrett, DA; Bennett, AJ; Chapman, V; Garle, MJ; Jhaveri, MD; Kendall, DA; Patel, A; Richardson, D; Robinson, I; Sagar, DR; Sun, Y, 2008) |
| "Anandamide (AEA) is an endogenous cannabinoid ligand acting predominantly on the cannabinoid 1 (CB(1)) receptor, but it is also an agonist on the capsaicin VR(1)/TRPV(1) receptor." | 1.32 | Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. ( Bölcskei, K; Helyes, Z; Németh, J; Pintér, E; Szolcsányi, J; Thán, M, 2003) |
| "Referred hyperalgesia to a somatopically appropriate superficial site is a cardinal symptom of visceral inflammatory pain and has been demonstrated after turpentine-induced urinary bladder inflammation in the rat." | 1.31 | Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. ( Farquhar-Smith, WP; Rice, AS, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 8 (23.53) | 29.6817 |
| 2010's | 21 (61.76) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Lang-Illievich, K | 1 |
| Klivinyi, C | 1 |
| Rumpold-Seitlinger, G | 1 |
| Dorn, C | 1 |
| Bornemann-Cimenti, H | 1 |
| Siracusa, R | 4 |
| Fusco, R | 4 |
| Cordaro, M | 4 |
| Peritore, AF | 2 |
| D'Amico, R | 2 |
| Gugliandolo, E | 4 |
| Crupi, R | 6 |
| Genovese, T | 1 |
| Evangelista, M | 3 |
| Di Paola, R | 4 |
| Cuzzocrea, S | 9 |
| Impellizzeri, D | 7 |
| Ardizzone, A | 1 |
| Casili, G | 1 |
| Lanza, M | 1 |
| Esposito, E | 5 |
| Britti, D | 1 |
| Schievano, C | 1 |
| Morittu, VM | 1 |
| Bartolucci, ML | 1 |
| Marini, I | 1 |
| Bortolotti, F | 1 |
| Bruschetta, G | 3 |
| Portelli, M | 1 |
| Militi, A | 1 |
| Oteri, G | 1 |
| Di Cesare Mannelli, L | 1 |
| D'Agostino, G | 3 |
| Pacini, A | 1 |
| Russo, R | 4 |
| Zanardelli, M | 1 |
| Ghelardini, C | 1 |
| Calignano, A | 4 |
| Starowicz, K | 1 |
| Makuch, W | 1 |
| Korostynski, M | 1 |
| Malek, N | 1 |
| Slezak, M | 1 |
| Zychowska, M | 1 |
| Petrosino, S | 1 |
| De Petrocellis, L | 1 |
| Cristino, L | 1 |
| Przewlocka, B | 1 |
| Di Marzo, V | 1 |
| Wang, J | 1 |
| Zhang, Q | 1 |
| Zhao, L | 1 |
| Li, D | 1 |
| Fu, Z | 1 |
| Liang, L | 1 |
| Khasabova, IA | 1 |
| Yao, X | 1 |
| Paz, J | 1 |
| Lewandowski, CT | 1 |
| Lindberg, AE | 1 |
| Coicou, L | 1 |
| Burlakova, N | 1 |
| Simone, DA | 1 |
| Seybold, VS | 1 |
| Donvito, G | 2 |
| Bettoni, I | 2 |
| Comelli, F | 2 |
| Colombo, A | 1 |
| Costa, B | 3 |
| Iuvone, T | 3 |
| Affaitati, G | 1 |
| De Filippis, D | 3 |
| Lopopolo, M | 1 |
| Grassia, G | 1 |
| Lapenna, D | 1 |
| Negro, L | 2 |
| Costantini, R | 1 |
| Vaia, M | 2 |
| Cipollone, F | 1 |
| Ialenti, A | 1 |
| Giamberardino, MA | 1 |
| Tronino, D | 1 |
| Offerta, A | 1 |
| Ostacolo, C | 1 |
| De Caro, C | 1 |
| Puglia, C | 1 |
| Blasi, P | 1 |
| Wilkerson, JL | 1 |
| Damaj, MI | 1 |
| Lichtman, AH | 1 |
| Jhaveri, MD | 1 |
| Richardson, D | 1 |
| Robinson, I | 1 |
| Garle, MJ | 1 |
| Patel, A | 1 |
| Sun, Y | 1 |
| Sagar, DR | 1 |
| Bennett, AJ | 1 |
| Alexander, SP | 1 |
| Kendall, DA | 1 |
| Barrett, DA | 1 |
| Chapman, V | 1 |
| Colleoni, M | 2 |
| Giagnoni, G | 2 |
| La Rana, G | 2 |
| Sasso, O | 3 |
| Iacono, A | 2 |
| Mattace Raso, G | 1 |
| Loverme, J | 1 |
| Piomelli, D | 2 |
| Meli, R | 2 |
| Luongo, L | 1 |
| Cipriano, M | 1 |
| Palazzo, E | 1 |
| Cinelli, MP | 2 |
| de Novellis, V | 1 |
| Maione, S | 1 |
| Vitiello, S | 1 |
| Raso, GM | 1 |
| Vallée, M | 1 |
| Piazza, PV | 1 |
| Romero, TR | 3 |
| Duarte, ID | 3 |
| Galdino, GS | 1 |
| Silva, GC | 1 |
| Resende, LC | 1 |
| Perez, AC | 1 |
| Cortes, SF | 1 |
| Pacheco, Dda F | 1 |
| Moreno-Sanz, G | 1 |
| Martucci, C | 1 |
| Realini, N | 1 |
| Dionisi, M | 1 |
| Mengatto, L | 1 |
| Duranti, A | 1 |
| Tarozzo, G | 1 |
| Tarzia, G | 1 |
| Mor, M | 1 |
| Bertorelli, R | 1 |
| Reggiani, A | 1 |
| Taylor, BK | 1 |
| Helyes, Z | 1 |
| Németh, J | 1 |
| Thán, M | 1 |
| Bölcskei, K | 1 |
| Pintér, E | 1 |
| Szolcsányi, J | 1 |
| Haller, VL | 1 |
| Cichewicz, DL | 1 |
| Welch, SP | 1 |
| Mazzari, S | 1 |
| Canella, R | 1 |
| Petrelli, L | 1 |
| Marcolongo, G | 1 |
| Leon, A | 1 |
| Jaggar, SI | 2 |
| Hasnie, FS | 1 |
| Sellaturay, S | 1 |
| Rice, AS | 3 |
| Farquhar-Smith, WP | 2 |
| Conti, S | 1 |
| Parolaro, D | 1 |
1 review available for palmidrol and Allodynia
| Article | Year |
|---|---|
New insights in mast cell modulation by palmitoylethanolamide.
Topics: Amides; Animals; Clinical Trials as Topic; Endocannabinoids; Ethanolamines; Humans; Hyperalgesia; In | 2013 |
1 trial available for palmidrol and Allodynia
| Article | Year |
|---|---|
The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial.
Topics: Amides; Analgesics; Anti-Inflammatory Agents; Cross-Over Studies; Double-Blind Method; Ethanolamines | 2022 |
32 other studies available for palmidrol and Allodynia
| Article | Year |
|---|---|
The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats.
Topics: Amides; Animals; Brain-Derived Neurotrophic Factor; Calcium-Binding Proteins; Ethanolamines; Extrace | 2020 |
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal; | 2021 |
A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
Topics: Administration, Oral; Amides; Animals; Anti-Inflammatory Agents; Carrageenan; Drug Combinations; Ede | 2017 |
Micronized palmitoylethanolamide reduces joint pain and glial cell activation.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Edema; Ethanolamin | 2018 |
The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Diabetic Neuropathies; | 2019 |
Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.
Topics: Amides; Animals; Blotting, Western; Endocannabinoids; Ethanolamines; Hyperalgesia; Immunohistochemis | 2013 |
Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
Topics: Amides; Amidohydrolases; Analgesia; Animals; Arachidonate 15-Lipoxygenase; Arachidonic Acids; Benzam | 2013 |
Down-regulation of PPARα in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats.
Topics: Amides; Animals; Diet, High-Fat; Down-Regulation; Ethanolamines; Hyperalgesia; Inflammation; Male; M | 2014 |
Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
Topics: Administration, Oral; Amides; Analgesics; Animals; Carrageenan; Chemistry, Pharmaceutical; Chromatog | 2014 |
JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.
Topics: Amides; Analgesics; Animals; Antineoplastic Agents; Arachidonic Acids; Benzodioxoles; Cells, Culture | 2014 |
Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes.
Topics: Amides; Analgesics; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Ethanolamines; | 2015 |
Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells.
Topics: Amides; Animals; Chymases; Disease Models, Animal; Endometriosis; Ethanolamines; Female; Hyperalgesi | 2016 |
Nanoparticles prolong N-palmitoylethanolamide anti-inflammatory and analgesic effects in vivo.
Topics: Adult; Amides; Analgesics; Animals; Anti-Inflammatory Agents; Calorimetry, Differential Scanning; Ca | 2016 |
A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Amides; Animals; Carrageenan; Cell Line, Tumor | 2016 |
Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice.
Topics: Amides; Amines; Animals; Cyclohexanecarboxylic Acids; Drug Synergism; Ethanolamines; Gabapentin; gam | 2016 |
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
Topics: Amides; Amidohydrolases; Animals; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Carrageen | 2008 |
The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.
Topics: Amides; Analgesics, Non-Narcotic; Animals; Cytoplasmic Granules; Drug Evaluation, Preclinical; Endoc | 2008 |
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia.
Topics: Amides; Analgesics; Animals; Butyrates; Carrageenan; Cell Nucleus; Central Nervous System; Cyclooxyg | 2009 |
Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats.
Topics: Amides; Animals; Carrageenan; Endocannabinoids; Ethanolamines; Ganglia, Spinal; Granuloma; Hyperalge | 2011 |
Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain.
Topics: Amides; Analgesics; Animals; Endocannabinoids; Ethanolamines; Hyperalgesia; Male; Mice; Pain; Pain M | 2012 |
N-palmitoyl-ethanolamine (PEA) induces peripheral antinociceptive effect by ATP-sensitive K+-channel activation.
Topics: Amides; Analgesics; Animals; Dequalinium; Dinoprostone; Disease Models, Animal; Dose-Response Relati | 2012 |
Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats.
Topics: Amides; Analgesics; Animals; Arginine; Cyclic GMP; Disease Models, Animal; Endocannabinoids; Ethanol | 2012 |
Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Topics: Amides; Analysis of Variance; Animals; Arachidonic Acids; Calcium Channel Blockers; Cannabinoid Rece | 2013 |
Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Burns; Carbamates; Carrageenan; Dose-Response Relation | 2013 |
N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Carbamates; Endocannabinoids; Enzyme Inhibitors; Ethan | 2013 |
Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat.
Topics: Amides; Animals; Arachidonic Acids; Calcitonin Gene-Related Peptide; Camphanes; Cannabinoids; Diterp | 2003 |
Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Topics: Acetaminophen; Amides; Analgesics; Animals; Arachidonic Acids; Benzamides; Benzoquinones; Camphanes; | 2006 |
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.
Topics: Amides; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cell De | 1996 |
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.
Topics: Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoids; Capillary Permeability; Cystitis; Elec | 1998 |
Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder.
Topics: Adjuvants, Immunologic; Amides; Analgesics; Animals; Arachidonic Acids; Area Under Curve; Cannabinoi | 2001 |
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat.
Topics: Acute Disease; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Cannabinoid Rece | 2002 |
Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.
Topics: Amides; Animals; Arachidonic Acids; Camphanes; Cannabinoid Receptor Modulators; Cannabinoids; Endoca | 2002 |